| abstract |
This invention provides methods of using Protein-tyrosine phosphatase (PTPase) inhibitors for lowering the cardiovascular risk profile in mammals experiencing or subject to type II diabetes or Syndrome X, including lowering levels of blood lipoproteins, free fatty acids and triglycerides, as well as treating, preventing or inhibiting atherosclerosis and other cardiovascular and cerebebrovascular disorders. |